Table 1.
Patient characteristics at baseline
| |
|
Intervention group (n = 30) |
Control group (n = 30) |
||
|---|---|---|---|---|---|
| n | % | n | % | ||
| Age (years) |
|
|
|
|
|
| |
Mean (SD) |
61.3 (10.1) |
|
64.1 (10.9) |
|
| Gender |
|
|
|
|
|
| |
Male |
14 |
46.7 |
19 |
63.3 |
| |
Female |
16 |
53.3 |
11 |
36.7 |
| Body Mass Index |
|
|
|
|
|
| |
Mean (SD) |
25.3 (4.5) |
|
24.4 (3.6) |
|
| Karnofsky PS (median, range) |
80 (70-100) |
|
80 (70-100) |
|
|
| Primary site |
|
|
|
|
|
| |
Lung |
12 |
9.2 |
8 |
26.6 |
| |
Breast |
5 |
16.7 |
6 |
20.1 |
| |
Prostate |
5 |
16.7 |
9 |
30.1 |
| |
Melanoma |
1 |
3.3 |
1 |
3.3 |
| |
Kidney |
1 |
3.3 |
2 |
6.7 |
| |
Other |
6 |
20.1 |
4 |
13.4 |
| Spinal metastases site |
|
|
|
|
|
| |
Thoracic |
17 |
56.7 |
14 |
46.7 |
| |
Lumbar |
9 |
30.0 |
13 |
43.3 |
| |
Thoracic and lumbar |
2 |
6.7 |
2 |
6.7 |
| |
Sacrum |
2 |
6.7 |
1 |
3.3 |
| Number of metastases |
|
|
|
|
|
| |
Mean (range) |
1.4 (2-4) |
|
1.7 (1-5) |
|
| |
Solitary |
22 |
73.3 |
18 |
60.0 |
| |
Multiple |
8 |
26.7 |
12 |
40.0 |
| Type of metastases |
|
|
|
|
|
| |
Mixed |
2 |
6.7 |
2 |
6.7 |
| |
Osteoblast |
9 |
30.0 |
10 |
33.3 |
| |
Osteolytic |
19 |
63.3 |
18 |
60.0 |
| Concomitant metastases at baseline |
|
|
|
||
| |
Visceral |
12 |
40.0 |
5 |
16.7 |
| |
Brain |
3 |
10.0 |
3 |
10.0 |
| |
Lung |
7 |
23.3 |
4 |
13.3 |
| |
Tissue |
8 |
26.7 |
6 |
20.0 |
| Hormonotherapy |
10 |
33.3 |
16 |
53.3 |
|
| Immunotherapy |
7 |
23.3 |
5 |
16.7 |
|
| Chemotherapy |
25 |
83.3 |
20 |
66.7 |
|
| Pathological fracture at baseline |
6 |
20.0 |
9 |
30.0 |
|
| Neurological deficit | 0 | 0.0 | 2 | 6.7 | |
SD Standard deviation.